Targeted immunotherapy against distinct cancer-associated fibroblasts overcomes treatment resistance in refractory HER2+ breast tumors

About 50% of human epidermal growth factor receptor 2 (HER2)+ breast cancer patients do not benefit from HER2-targeted therapy and almost 20% of them relapse after treatment. Here, we conduct a detailed analysis of two independent cohorts of HER2+ breast cancer patients treated with trastuzumab to e...

Descripción completa

Detalles Bibliográficos
Autores principales: Rivas, Elisa I., Linares, Jenniffer, Zwick, Melissa, Gómez-Llonin, Andrea, Guiu, Marc, Labernadie, Anna, Badia-Ramentol, Jordi, Lladó, Anna, Bardia, Lídia, Pérez-Núñez, Iván, Martínez-Ciarpaglini, Carolina, Tarazona, Noelia, Sallent-Aragay, Anna, Garrido, Marta, Celià-Terrassa, Toni, Burgués, Octavio, Gomis, Roger R., Albanell, Joan, Calon, Alexandre
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9463158/
https://www.ncbi.nlm.nih.gov/pubmed/36085201
http://dx.doi.org/10.1038/s41467-022-32782-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9463158/
https://www.ncbi.nlm.nih.gov/pubmed/36085201
http://dx.doi.org/10.1038/s41467-022-32782-3

Ejemplares similares